The Pharmacogenomics and Experimental Therapeutics (PhET) Program is a cohesive, integrated group that brings together a diverse team of 48 members representing 9 different Departments. PhET interfaces with all of the other Programs to integrate fundamental cancer research with clinical care and clinical research objectives. The overall goal of the Program is to foster interaction between basic and clinical investigators, with a focus on pharmacogenomics and innovative molecular targets that are evaluated in the context of bio- or genetic- marker driven clinical trials at all phases of drug development, with the ultimate goal of developing innovative, personalized and effective therapies for cancer patients. The two program coleaders, M. Eileen Dolan, PhD, a laboratory-based scientist with experience in preclinical and translational studies, and Walter Stadler, MD, a physician-scientist with expertise in clinical trials and clinical drug development, work well together to promote the goals of the PhET Program. The Program's investigators have made major contributions including the identification of putative pharmacogenomic predictors of cancer therapeutic efficacy and toxicity, elucidation of predictive biomarkers of molecular pathway-directed therapy, and discovery of DNA repair mechanisms that have the potential for being therapeutic targets. Pharmacogenomic research within the program interfaces with basic research, translational, clinical and implementation science. The discoveries and contributions span the entire spectrum of translational research including classic """"""""bench-to-bedside"""""""" and """"""""bedside-to-bench"""""""" concepts (i.e., """"""""T1 translation""""""""), as well as translation from research to practice in what has been termed 'T2"""""""" translation or implementation science. The integrated scientific themes are: 1) Translational pharmacogenomic studies through pathway-directed as well as unbiased discovery approaches in model and clinical systems; 2) Development of novel therapeutic molecular targets, including angiogenesis, DNA repair, and defined molecular pathways; 3) Novel Phase I, II, and III biomarker-driven clinical trials, including the development of combined modality approaches, and novel clinical trial designs;and 4) Studies to incorporate biomarkers, and especially pharmacogenomic biomarkers, into clinical care.

Public Health Relevance

The Pharmacogenomics and Experimental Therapeutics program is the clinical and translational component of the University of Chicago Comprehensive Cancer Center and provides expertise in evaluation of molecular therapeutic targets to implementation in a clinical setting, with an emphasis on pharmacogenomics.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351

Showing the most recent 10 out of 668 publications